News
Clarity receives FDA Fast Track approval for 64Cu-SAR-bisPSMA
SYDNEY, 22 August 2024 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop
5 Minute